Provided by Tiger Trade Technology Pte. Ltd.

Eli Lilly

878.24
-18.7600-2.09%
Post-market: 875.00-3.2400-0.37%19:59 EDT
Volume:2.74M
Turnover:2.43B
Market Cap:830.27B
PE:38.27
High:900.83
Open:896.00
Low:877.11
Close:897.00
52wk High:1,133.95
52wk Low:623.78
Shares:945.38M
Float Shares:945.00M
Volume Ratio:0.94
T/O Rate:0.29%
Dividend:6.00
Dividend Rate:0.68%
EPS(TTM):22.95
EPS(LYR):22.95
ROE:101.16%
ROA:19.42%
PB:31.29
PE(LYR):38.27

Loading ...

RBC Capital Markets Pounds the Table on Eli Lilly Stock (LLY) as Share Price Falls

TIPRANKS
·
Mar 17

Lilly's EBGLYSS (Lebrikizumab-Lbkz) Is The First And Only Selective Il-13 Inhibitor To Deliver Positive Phase 3 Outcomes In Patients Aged Six Months To 18 Years With Moderate-To-Severe Atopic De

Reuters
·
Mar 16

Eli Lilly - New Zepbound (Tirzepatide) Kwikpen Starting at $299 per Month for 2.5 Mg Dose

THOMSON REUTERS
·
Mar 16

Eli Lilly - Zepbound (Tirzepatide) Kwikpen NOW Available at Self-Pay Pricing at Major Pharmacies Nationwide in Addition to Lillydirect

THOMSON REUTERS
·
Mar 16

Eli Lilly reports Phase 3 ADorable-1 trial shows EBGLYSS achieves 63% EASI-75 and 44% IGA 0/1 at week 16 in pediatric atopic dermatitis

Reuters
·
Mar 16

Lilly's Ebglyss (Lebrikizumab-Lbkz) Is the First and Only Selective Il-13 Inhibitor to Deliver Positive Phase 3 Outcomes in Patients Aged Six Months to 18 Years With Moderate-to-Severe Atopic Dermatitis

THOMSON REUTERS
·
Mar 16

Eli Lilly - Announces Positive Phase 3 Results for Ebglyss in Pediatric Atopic Dermatitis

THOMSON REUTERS
·
Mar 16

Eli Lilly - in Phase 3, 63% Achieved Easi-75 and 44% Achieved Iga 0,1 at Week 16

THOMSON REUTERS
·
Mar 16

Eli Lilly - Ebglyss Safety Profile Consistent With Prior Studies; No Injection Site Pain Reported

THOMSON REUTERS
·
Mar 16

Eli Lilly - to Submit Data for Potential Label Update to U.S. and Global Regulators

THOMSON REUTERS
·
Mar 16

Eli Lilly (LLY) Valuation After China GLP‑1 Expansion And Tirzepatide Safety Push

Simply Wall St.
·
Mar 16

Lilly’s China Bet and U.S. Access Push Could Be A Game Changer For Eli Lilly (LLY)

Simply Wall St.
·
Mar 14

Kroger to Offer Eli Lilly's Zepbound KwikPen With Expanded Access to Savings Program

Dow Jones
·
Mar 13

Kroger Brings Zepbound® Kwikpen to Retail Pharmacy, Expanding Access and Savings for Self-Pay Patients

THOMSON REUTERS
·
Mar 13

Eli Lilly & Co (LLY) Receives a Buy from Bernstein

TIPRANKS
·
Mar 13

Sector Update: Health Care Stocks Lower in Afternoon Trading

MT Newswires Live
·
Mar 13

Lilly finds impurity in compounded version of its weight-loss drug, warns of health risks

Reuters
·
Mar 13

Eli Lilly Cautions Against Blending Tirzepatide with Other Substances

Stock News
·
Mar 12

Market Chatter: Eli Lilly Expands in China with $3 Billion Supply Chain Investment

MT Newswires Live
·
Mar 12

BRIEF-Eli Lilly Issues Warning About Potential Safety Risks Of Tirzepatide Compounded With Vitamin B12

Reuters
·
Mar 12